News & Events
The Archives of Pathology and Laboratory Medicine recently published an article by a group from the Department of Pathology and Genomic Medicine at Houston Methodist Hospital who performed a clinical validation of the Insight ALK Screen qPCR assay which is manufactured and distributed globally by QIAGEN as ALK RGQ RT-PCR Kit.
Insight Genetics, Inc. today announced that Ronald (Ronnie) Andrews Jr., former president of the Genetic Science Division of Thermo Fisher Scientific, has been named to the company’s Board of Directors. Andrews also joined the company’s base of private investors, in a round of $3 Million growth capital that will allow Insight Genetics to expand and expedite its triple negative breast cancer and non-small cell lung cancer programs. The minimum of $3 million has been closed, with a maximum of $5 million targeted.
Insight Genetics will attend the Association for Molecular Pathology (AMP) 2015 Annual Meeting in Austin, Texas from November 4-7, 2015. At the event, Insight Genetics will be available to discuss its current programs focused on enabling precision medicine in non-small cell lung cancer and triple-negative breast cancer as well as its service offerings including custom assay design and development and specialized pharmaceutical services.
Insight Genetics Presents Poster at the 16th World Conference on Lung Cancer and Attends the World CDx Boston Summit
Insight Genetics presented a poster on September 7 at the International Association for the Study of Lung Cancer’s 16th Annual World Conference on Lung Cancer in Denver and will attend the 6th Annual World CDx Boston Summit from September 8-10.
Insight Genetics, Inc. today announced the launch of its Insight RET Screen™, a Clinical Laboratory Improvement Amendments (CLIA)-validated assay available through Insight Molecular Labs, that detects oncogenic RET (Rearranged during Transfection) expression in non-small cell lung cancer (NSCLC) patients.